Your browser doesn't support javascript.
loading
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
Pollard, Rodney P E; Abdulahad, Wayel H; Vissink, Arjan; Hamza, Nishath; Burgerhof, Johannes G M; Meijer, Jiska M; Visser, Annie; Huitema, Minke G; Spijkervet, Fred K L; Kallenberg, Cees G M; Bootsma, Hendrika; Kroese, Frans G M.
Ann Rheum Dis ; 72(1): 146-8, 2013 Jan.
Article in En | MEDLINE | ID: mdl-22851468
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / Antirheumatic Agents / B-Cell Activating Factor / Tumor Necrosis Factor Ligand Superfamily Member 13 / Antibodies, Monoclonal, Murine-Derived Type of study: Clinical_trials Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2013 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sjogren's Syndrome / Antirheumatic Agents / B-Cell Activating Factor / Tumor Necrosis Factor Ligand Superfamily Member 13 / Antibodies, Monoclonal, Murine-Derived Type of study: Clinical_trials Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2013 Document type: Article Country of publication: